Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Go back to Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.76 | 52 Week High | $45.58 | |||
| Open | $50.76 | 52 Week Low | $37.82 | |||
| Day High | $50.76 | P/E | N/A | |||
| Day Low | $50.76 | EPS | $0.00 | |||
| Volume | 5,467 | |||||
| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.76 | 52 Week High | $45.58 | |||
| Open | $50.76 | 52 Week Low | $37.82 | |||
| Day High | $50.76 | P/E | N/A | |||
| Day Low | $50.76 | EPS | $0.00 | |||
| Volume | 5,467 | |||||
